Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Interest Expenses (2021 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Interest Expenses for 3 consecutive years, with $1.1 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Interest Expenses rose 57.14% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Mar 2024, down 67.81%, and an annual FY2023 reading of $1.9 million, down 39.97% over the prior year.
  • Interest Expenses was $1.1 million for Q2 2023 at Alaunos Therapeutics, up from $900000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.1 million in Q2 2023 and bottomed at $444000.0 in Q3 2021.
  • Average Interest Expenses over 3 years is $800000.0, with a median of $778000.0 recorded in 2021.
  • The sharpest move saw Interest Expenses soared 80.18% in 2022, then surged 31.77% in 2023.
  • Year by year, Interest Expenses stood at $756000.0 in 2021, then surged by 34.52% to $1.0 million in 2022, then increased by 8.16% to $1.1 million in 2023.
  • Business Quant data shows Interest Expenses for TCRT at $1.1 million in Q2 2023, $900000.0 in Q1 2023, and $1.0 million in Q4 2022.